Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine

References

• KhouryMJValdezRAlbrightAPublic health genomics approach to type 2 diabetesDiabetes200857112911291418971439
   PubMed Web of Science ®Google Scholar
• McCarthyMIZegginiEGenome-wide association scans for type 2 diabetes: new insights into biology and therapyTrends Pharmacol Sci2007281259860117997168
   PubMed Web of Science ®Google Scholar
• KhouryMJGenetics and genomics in practice: the continuum from genetic disease to genetic information in health and diseaseGenet Med20035426126812865755
   PubMed Web of Science ®Google Scholar
• EpsteinRSFruehFWGerenDPayer perspectives on pharmacogenomics testing and drug developmentPharmacogenomics200910114915119102724
   PubMed Web of Science ®Google Scholar
• PearsonTAManolioTAHow to interpret a genome-wide association studyJAMA2008299111335134418349094
   PubMed Web of Science ®Google Scholar
• SadéeWDaiZPharmacogenetics/genomics and personalized medicineHum Mol Genet200514Spec No. 2R207R21416244319
   PubMed Web of Science ®Google Scholar
• SattirajuSReyesSKaneGCTerzicAK(ATP) channel pharmacogenomics: from bench to bedsideClin Pharmacol Ther200883235435717957187
   PubMed Web of Science ®Google Scholar
• ZhangWHuangSDolanEIntegrating epigenomics into pharmacogenomic studiesPharmacogenomics and Personalized Medicine2008171420622972
   PubMedGoogle Scholar
• PerryJRFraylingTMNew gene variants alter type 2 diabetes risk predominantly through reduced beta-cell functionCurr Opin Clin Nutr Metab Care200811437137718541994
   PubMed Web of Science ®Google Scholar
• KirchheinerJRootsIGoldammerMRosenkranzBBrockmollerJEffect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevanceClin Pharmacokinet200544121209122516372821
   PubMed Web of Science ®Google Scholar
• John Wiley & Sons, LtdCurrent literature in diabetesDiabetes Metab Res Rev200982710.1002/dmrr
   Google Scholar
• NeeliHGadiRRaderDJManaging diabetic dyslipidemia: beyond statin therapyCurr Diab Rep200991111719192419
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationEconomic costs of diabetes in the U.S. In 2007Diabetes Care200831359661518308683
   PubMed Web of Science ®Google Scholar
• MisraAKhuranaLObesity and the metabolic syndrome in developing countriesJ Clin Endocrinol Metab20089311 Suppl 1S9S3018987276
   PubMed Web of Science ®Google Scholar
• RipsinCMKangHUrbanRJManagement of blood glucose in type 2 diabetes mellitusAm Fam Physician2009791293619145963
   PubMed Web of Science ®Google Scholar
• WolfordJKVozarova de CourtenBGenetic basis of type 2 diabetes mellitus: implications for therapyTreat Endocrinol20043425726716026108
   PubMedGoogle Scholar
• ReitmanMLSchadtEEPharmacogenetics of metformin response: a step in the path toward personalized medicineJ Clin Invest200711751226122917476355
   PubMed Web of Science ®Google Scholar
• TakaneHShikataEOtsuboKHiguchiSIeiriIPolymorphism in human organic cation transporters and metformin actionPharmacogenomics20089441542218384255
   PubMed Web of Science ®Google Scholar
• FowlerMMicrovascular and macrovascular complication of diabetesDiabetes Care20087627782
   Google Scholar
• ShikataEYamamotoRTakaneHHuman organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metforminJ Hum Genet200752211712217111267
   PubMed Web of Science ®Google Scholar
• ShuYSheardownSABrownCEffect of genetic variation in the organic cation transporter 1 (OCT1) on metformin actionJ Clin Invest200711751422143117476361
   PubMed Web of Science ®Google Scholar
• BeckerMLVisserLEvan SchaikRHHofmanAUitterlindenAGStrickerBHGenetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose lowering effect of metformin in patients with diabetes mellitus: a preliminary studyDiabetes200958374574919228809
   PubMed Web of Science ®Google Scholar
• SongISShinHJShimEJGenetic variants of the organic cation transporter 2 influence the disposition of metforminClin Pharmacol Ther200884555956218401339
   PubMed Web of Science ®Google Scholar
• KimuraNMasudaSTaniharaYMetformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1Drug Metab Pharmacokinet200520537938616272756
   PubMedGoogle Scholar
• OtsukaMMatsumotoTMorimotoRAriokaSOmoteHMoriyamaYA human transporter protein that mediates the final excretion step for toxic organic cationsProc Natl Acad Sci U S A200510250179231792816330770
   PubMed Web of Science ®Google Scholar
• MoriyamaYHiasaMMatsumotoTOmoteHMultidrug and toxic compound extrusion (MATE)-type proteins as anchor transporters for the excretion of metabolic waste products and xenobioticsXenobiotica2008387–81107111818668441
   PubMed Web of Science ®Google Scholar
• TaniharaYMasudaSSatoTKatsuraTOgawaOInuiKSubstrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiportersBiochem Pharmacol200774235937117509534
   PubMed Web of Science ®Google Scholar
• WangDSJonkerJWKatoYKusuharaHSchinkelAHSugiyamaYInvolvement of organic cation transporter 1 in hepatic and intestinal distribution of metforminJ Pharmacol Exp Ther2002302251051512130709
   PubMed Web of Science ®Google Scholar
• WangZJYinOQTomlinsonBChowMSOCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidinePharmacogenet Genomics200818763764518551044
   PubMed Web of Science ®Google Scholar
• TarasovAINicolsonTJRivelineJPA rare mutation in ABCC8/SUR1 leading to altered ATP-sensitive K+ channel activity and beta-cell glucose sensing is associated with type 2 diabetes in adultsDiabetes20085761595160418346985
   PubMed Web of Science ®Google Scholar
• KosterJCRemediMSDaoCNicholsCGATP and sulfonylurea sensitivity of mutant ATP-sensitive K+ channels in neonatal diabetes: implications for pharmacogenomic therapyDiabetes20055492645265416123353
   PubMed Web of Science ®Google Scholar
• BabenkoAPPolakMCaveHActivating mutations in the ABCC8 gene in neonatal diabetes mellitusN Engl J Med2006355545646616885549
   PubMed Web of Science ®Google Scholar
• GloynALPearsonERAntcliffJFActivating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetesN Engl J Med2004350181838184915115830
   PubMed Web of Science ®Google Scholar
• TammaroPFlanaganSEZadekBA Kir6.2 mutation causing severe functional effects in vitro produces neonatal diabetes without the expected neurological complicationsDiabetologia200851580281018335204
   PubMed Web of Science ®Google Scholar
• ProksPShimomuraKCraigTJGirardCAAshcroftFMMechanism of action of a sulphonylurea receptor SUR1 mutation (F132L) that causes DEND syndromeHum Mol Genet200716162011201917584766
   PubMed Web of Science ®Google Scholar
• WagnerVMKremkeBHiortOFlanaganSEPearsonERTransition from insulin to sulfonylurea in a child with diabetes due to a mutation in KCNJ11 encoding Kir6.2-initial and long-term response to sulfonylurea therapyEur J Pediatr2009168335936118548275
   PubMed Web of Science ®Google Scholar
• SagenJVRaederHHathoutEPermanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapyDiabetes200453102713271815448106
   PubMed Web of Science ®Google Scholar
• GloynALReimannFGirardCRelapsing diabetes can result from moderately activating mutations in KCNJ11Hum Mol Genet200514792593415718250
   PubMed Web of Science ®Google Scholar
• PearsonERFlechtnerINjølstadPRswitching from insulin to oral sulfonylurea’s in patients with diabetes due to Kir6.2 mutationsN Engl J Med200635546747716885550
   PubMed Web of Science ®Google Scholar
• FengYGuangyunMXiaoweiRSer1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patientsDiabetes Care200831101939194418599530
   PubMed Web of Science ®Google Scholar
• BeckerMLVisserLETrienekensPHHofmanAvan SchaikRHStrickerBHCytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitusClin Pharmacol Ther200883228829217597710
   PubMed Web of Science ®Google Scholar
• PearsonERDonnellyLAKimberCVariation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs studyDiabetes20075682178218217519421
   PubMed Web of Science ®Google Scholar
• AquilanteCLPharmacogenetics of thiazolidinedione therapyPharmacogenomics20078891793117716227
   PubMed Web of Science ®Google Scholar
• BohmeMNitzIDoringFKlapperMAnalysis of the transcriptional regulation of the FABP2 promoter haplotypes by PPARgamma/RXRalpha and Oct-1Biochim Biophys Acta200817791061662118634911
   PubMed Web of Science ®Google Scholar
• LudovicoOPellegriniFDi PaolaRHeterogeneous effect of peroxisome proliferator-activated receptor gamma2 Ala12 variant on type 2 diabetes riskObesity (Silver Spring)20071551076108117495182
   PubMed Web of Science ®Google Scholar
• BluherMLubbenGPaschkeRAnalysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetesDiabetes Care200326382583112610044
   PubMed Web of Science ®Google Scholar
• DeebSSFajasLNemotoMA Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivityNat Genet19982032842879806549
   PubMed Web of Science ®Google Scholar
• MasugiJTamoriYMoriHKoikeTKasugaMInhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesisBiochem Biophys Res Commun2000268117818210652233
   PubMed Web of Science ®Google Scholar
• KangESParkSYKimHJEffects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma2 gene on rosiglitazone response in type 2 diabetesClin Pharmacol Ther200578220220816084854
   PubMed Web of Science ®Google Scholar
• SnitkerSWatanabeRMAniIChanges in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) studyDiabetes Care20042761365136815161789
   PubMed Web of Science ®Google Scholar
• FlorezJCJablonskiKASunMWEffects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazoneJ Clin Endocrinol Metab20079241502150917213274
   PubMed Web of Science ®Google Scholar
• KangESParkSYKimHJThe influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetesDiabetes Care20052851139114415855579
   PubMed Web of Science ®Google Scholar
• SaadMFGrecoSOseiKRagaglitazar Dose-Ranging Study GroupRagaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone armDiabetes Care20042761324132915161783
   PubMed Web of Science ®Google Scholar
• RaskinPKlaffLMcGillJEfficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metforminDiabetes Care20032672063206812832314
   PubMed Web of Science ®Google Scholar
• ZhangWHeYJHanCTEffect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinideBr J Clin Pharmacol200662556757216796707
   PubMed Web of Science ®Google Scholar
• KalliokoskiANeuvonenMNeuvonenPJNiemiMDifferent effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinideJ Clin Pharmacol200848331132118187595
   PubMed Web of Science ®Google Scholar